Efficacy and safety of darolutamide in Black/African-American patients from the Phase III ARAMIS study

Future Oncology, our partner journal, has recently published a Short Communication Article, which provides information on the effect of darolutamide in the 52 Black/African-American patients who took part in the Phase III ARAMIS trial. Abstract: Background: Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the Phase III ARAMIS study. We evaluated outcomes in Black/African-American patients in ARAMIS. Materials & Methods: Patients with nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide (n=955) or placebo (n=554) plus androgen-deprivation therapy. The primary endpoint was MFS. Secondary endpoints included OS and safety. Results: In 52 (3.4%) Black/African-American patients,...